Skip to site menu Skip to page content

Daily Newsletter

17 October 2023

Daily Newsletter

17 October 2023

Spring Fertility to open new Portland location next year

The centre plans to begin accepting patient appointments in Portland from January 2024.

October 17 2023

US-based fertility centre Spring Fertility is set to open a new location in Portland, Oregon, US, in the second quarter of 2024.

The clinic will bring individualised fertility care to the Pacific Northwest, offering services, including egg freezing, IVF, and reproductive services.

Spring chief medical officer and co-founder Dr Nam Tran said: “We are excited to continue to lead and participate in research studies and find ways to safely study, test and ultimately deliver meaningful advances to improve the quality of fertility care for our patients.

“We hope not only to assist with exceptional medical care but to contribute to the scientific community in Portland and beyond.”

Similar to other Spring Fertility clinics, the Portland location also claims to provide quality, personalised care to individuals seeking fertility preservation.

The centre plans to begin accepting patient appointments in Portland from January 2024.

Spring Fertility is a fertility platform operating in multiple locations across the US. It looks to set up a new IVF centre in 2025.

Spring co-founder Dr Peter Klatsky said: “Since Spring’s opening in 2016, we have supported thousands of people, both in the Bay Area and Manhattan, as well as from across the globe, on their path to parenthood.

“Opening a fertility clinic in the Pacific Northwest allows us to provide even more access to the level of care and personalised experience that Spring has become known for.

“At Spring, we measure success in two primary areas: First, we must provide the most supportive, individualised patient experience.

“Then we must provide the best clinical outcomes, anywhere.”

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close